Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Endothelin in congestive heart failure

M P Love1, J J McMurray

  • 1Medical Research Council, University of Glasgow, Scotland, UK.

Basic Research in Cardiology
|January 1, 1996
PubMed
Summary

Endothelin (ET) plays a role in congestive heart failure (CHF). Blocking ET actions or generation may offer new therapeutic strategies for CHF patients, potentially improving outcomes beyond current treatments like ACE inhibitors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia--the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT).

Journal of human hypertension·2015
Same author

Change in levels of physical activity after diagnosis of type 2 diabetes: an observational analysis from the NAVIGATOR study.

Diabetes, obesity & metabolism·2014
Same author

B-type natriuretic peptide and glycaemia: an emerging cardiometabolic pathway?

Diabetologia·2012
Same author

Angiotensin II receptor antagonists for the treatment of heart failure: what is their place after ELITE-II and Val-HeFT?

Journal of the renin-angiotensin-aldosterone system : JRAAS·2002
Same author

Effects of sympathetic inhibition on exertional dyspnoea, ventilatory and metabolic responses to exercise in normotensive humans.

Clinical science (London, England : 1979)·2002
Same author

Effect of chronic angiotensin II type I receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic variables in patients with heart failure.

Thrombosis and haemostasis·2002

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Endothelin (ET) peptides exert significant vascular, cardiac, and renal effects.
  • These actions are potentially important in the pathophysiology of congestive heart failure (CHF).
  • Current CHF treatments, including ACE inhibitors, have limitations, with high morbidity and mortality persisting.

Purpose of the Study:

  • To investigate the role of ET in CHF pathophysiology.
  • To evaluate the therapeutic potential of anti-ET drugs in CHF.
  • To explore novel therapeutic strategies for CHF.

Main Methods:

  • In vivo studies using selective and non-selective ET receptor antagonists.
  • Investigating the potential of endothelin converting enzyme (ECE) inhibitors.

Main Results:

  • ET receptor antagonists are required to clarify ET's role in CHF.
  • Anti-ET agents show potential for hemodynamic benefit beyond ACE inhibitors.
  • ECE inhibition offers an alternative investigative and therapeutic approach.

Conclusions:

  • Blockade of ET actions or generation warrants further investigation for CHF.
  • New therapeutic strategies targeting ET may improve CHF management.
  • Anti-ET therapies hold promise for patients with high morbidity and mortality from CHF.

Related Experiment Videos